drugset / Trial / NCT07446257
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
Phase 0
Not yet recruiting
60 enrolled
University of Texas Southwestern Medical Center
Maia Biotechnology · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Timeline
- Start
- 2026-06-29
- Primary completion
- 2029-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | ateganosine | Small molecule | 60 mg | Intravenous |